Survival outcomes after minimally invasive thymectomy for early-stage thymic carcinoma

Minimally invasive surgery (MIS) has occasionally been used for selected patients with thymoma, but there is little information on the MIS approach for thymic carcinoma. The aim of this study was to evaluate survival outcomes after MIS for early-stage (Masaoka stage I–II) thymic carcinoma and thymic...

Full description

Saved in:
Bibliographic Details
Published in:Surgery today (Tokyo, Japan) Japan), 2019-04, Vol.49 (4), p.357-360
Main Authors: Miyata, Ryo, Hamaji, Masatsugu, Omasa, Mitsugu, Nakagawa, Tatsuo, Sumitomo, Ryota, Huang, Cheng-Long, Ikeda, Masaki, Fujinaga, Takuji, Shoji, Tsuyoshi, Katakura, Hiromichi, Motoyama, Hideki, Nakajima, Daisuke, Ohsumi, Akihiro, Menju, Toshi, Aoyama, Akihiro, Chen-Yoshikawa, Toyofumi F., Sato, Toshihiko, Sonobe, Makoto, Date, Hiroshi
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Minimally Invasive Surgical Procedures - methods
Neoplasm Staging
Retrospective Studies
Short Communication
Surgery
Surgical Oncology
Survival Rate
Thymectomy - methods
Thymoma - mortality
Thymoma - surgery
Thymus Neoplasms - mortality
Thymus Neoplasms - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Minimally invasive surgery (MIS) has occasionally been used for selected patients with thymoma, but there is little information on the MIS approach for thymic carcinoma. The aim of this study was to evaluate survival outcomes after MIS for early-stage (Masaoka stage I–II) thymic carcinoma and thymic neuroendocrine carcinoma. A retrospective chart review of the cases recorded in our multi-institutional database was performed to identify patients who underwent resection for thymic carcinoma between 1995 and 2017. MIS thymectomy was performed in 17 cases (VATS, n  = 14; RATS, n  = 3. male, 41%; median age, 72 years). The median follow-up period was 32.7 (range 7.4–106) months. The five-year overall survival and relapse-free survival rates were 84.4% and 77.8%, respectively. The present study demonstrated encouraging preliminary results regarding MIS for the treatment of early-stage thymic carcinoma and thymic neuroendocrine carcinoma. Further studies with a larger sample size are required to evaluate the indications for this surgery.
ISSN:0941-1291
1436-2813
DOI:10.1007/s00595-018-1740-x